Abstract:Tankyrase (TNKS) enzymes remained central biotargets to treat Wnt-driven colorectal cancers. The success of Olaparib posited the druggability of PARP family enzymes depending on their role in tumor proliferation. In this work, an MD-simulation-based comparative assessment of the protein–ligand interactions using the best-docked poses of three selected compounds (two of the designed and previously synthesized molecules obtained through molecular docking and one reported TNKS inhibitor) was performed for a 500 ns period. The PDB:ID-7KKP and 3U9H were selected for TNKS1 and TNKS2, respectively. The Molecular Mechanics Generalized Born Surface Area (MM-GBSA) based binding energy data exhibited stronger binding of compound-15 (average values of −102.92 and −104.32 kcal/mol for TNKS1 and TNKS2, respectively) as compared to compound-22 (average values of −82.99 and −85.68 kcal/mol for TNKS1 and TNKS2, respectively) and the reported compound-32 (average values of −81.89 and −74.43 kcal/mol for TNKS1 and TNKS2, respectively). Compound-15 and compound-22 exhibited comparable or superior binding to both receptors forming stable complexes when compared to that of compound-32 upon examining their MD trajectories. The key contributors were hydrophobic stacking and optimum hydrogen bonding allowing these molecules to occupy the adenosine pocket by interfacing D-loop residues. The results of bond distance analysis, radius of gyration, root mean square deviation, root mean square fluctuation, snapshots at different time intervals, LUMO–HUMO energy differences, electrostatic potential calculations, and binding free energy suggested better binding efficiency for compound-15 to TNKS enzymes. The computed physicochemical and ADMET properties of compound-15 were encouraging and could be explored further for drug development. Communicated by Ramaswamy H. Sarma

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors

Design, synthesis, and biological evaluation of isoquinolin-1(2 H)-one derivates as tankyrase-1/2 inhibitors

New molecular insights for 4H-1,2,4-triazole derivatives as inhibitors of tankyrase and Wnt-signaling antagonist: a molecular dynamics simulation study

Substitutions at the C-8 position of quinazolin-4-ones improve the potency of nicotinamide site binding tankyrase inhibitors

New 3-[(4-hydroxy-6-methly-2(1h)-pyridinones)-3-yl]-4-substituted-(1h)1,2,4- Triazole-5-Thiones: Efficient Synthesis, X-Ray Crystallographic Analysis, and Antitumor Activity

Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.

Development of Novel Selective Pharmacophore for Tankyrase Inhibitors

Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation

Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors

Synthesis, anticancer evaluation, molecular docking and ADME study of novel pyrido[4ʹ,3ʹ:3,4]pyrazolo[1,5-a]pyrimidines as potential tropomyosin receptor kinase A (TrKA) inhibitors

Recent advances in the structure-based rational design of TNKSIs.

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent

Design, Synthesis and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides As Potent and Selective Pan-Tropomyosin Receptor Kinase (TRK) Inhibitors.

Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6h-pyrimido[5,4-b][1,4]oxazin-7(8h)-one Derivatives As A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.

Design, Synthesis and Biological Activity of Bicyclic Carboxamide Derivatives As TRK Inhibitors

Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6 H-pyrimido[5,4- b][1,4]oxazin-7(8 H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants

Design, Synthesis and Evaluation of Novel 5-Phenylpyridin-2(1h)-one Derivatives As Potent Reversible Bruton's Tyrosine Kinase Inhibitors.

Design, Synthesis and Evaluate of Indazolylaminoquinazoline Derivatives As Potent Tropomyosin Receptor Kinase (TRK) Inhibitors

Identification of Novel Thiazolo[5,4-<i>b</i>]Pyridine Derivatives as Potent Phosphoinositide 3-Kinase Inhibitors

Structure-based Design and SAR Development of 5,6-Dihydroimidazolo[1,5-f]pteridine Derivatives As Novel Polo-like Kinase-1 Inhibitors.

Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships